HUE026491T2 - Benztiazol-származékok mint rákellenes szerek - Google Patents
Benztiazol-származékok mint rákellenes szerek Download PDFInfo
- Publication number
- HUE026491T2 HUE026491T2 HUE09775337A HUE09775337A HUE026491T2 HU E026491 T2 HUE026491 T2 HU E026491T2 HU E09775337 A HUE09775337 A HU E09775337A HU E09775337 A HUE09775337 A HU E09775337A HU E026491 T2 HUE026491 T2 HU E026491T2
- Authority
- HU
- Hungary
- Prior art keywords
- compound
- cyano
- group
- mmol
- ethyl acetate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
Claims (3)
- Szabadalmi igénypontok L (Π képktö vegyük! Π) ~a képletbenR3 Jelentése egy vagy abttfesopoft egy vagy több he lyettesítővel adott esetbeo szohszîitaâh: Ç:^8 eikioatkiesopost vagy egy vagy több hetysttesttóvei adott ekéíboo ssisbsKtitaái heterociklusos csoport; X jeteetése -Ctt vagy ehíRtb, Äel Re jelentése hídrogőmítotti vagy Cj alldiesepöüt;Y jekaiésevagy képlett; csoport, ahol az A g\ üni adott esetbe« tovább szabsztstöáRbeOzöígyíirá; Zjeiersiésü ( ; ) · NR’CÖ··, C) -NR^CO-W*-. i '}) -N R'4CO«W·0 ·, (4 ) -NR*!CO-W b-O- W·3-. (5) -Nl^CO-W^S-, í6}-NR3CO-W;.RRA; (? ! -NR 'COö·-» P) .rN^CO-CO-, (9) -NR^CüNR·*-, ; 0) -HR^COHRk-Wk, (1!)-NR3COKRk\yb<> vagy ( í 2 )· -CONR ·- kepíbsi csopofk akd R J és Rd otiadegytypek jelentése egymástól fôggetlemR mámgónaíom vttgy a&il* iísopon, W* vs tükiclsgyíkénsl jeJgotése egymástól S5ggetlpr?bl tSty vagy több helyettesítővel adott esetben sznbsattttiib Cj>s aJkikoesopoit, egy vagy több belyedesítóvei adott esetbe;) sz«bs.d:tRíá;í %..yalketüláncsopoíl êg5' vagy több heiyeöeshövd adót: esetibpoS^bsxSíaált C2»ő aikisdéoesofvïrî vagy egy vagy több Mys&esÄ·· vei adott esetben ?z«bs?< ituaU C3 ^ elkiosikileaesopori; bejelentése agy vagy több helyettes abvc: adóit esetben saubszdtuálk 3* Vagy b-tapk gyűrű; és Rá jakoRise ciano csoport -vagys#, % Az L igénypont saemtU vegyidet. ahoi RÁ jelentése (1} egy vagy tóbb helyettesítővel adóit esetben sauhsvtiiuált C;.^ aikilcsopott. <2} egy vagy#feb helyettesítővel acted: esetben szítbszííbtált C3„g; cskioatkiicsoport vagy (3 i egy vagy több helyertexitővei adod esetben sznbsahíMh, 3 ~ iMagű, ffionocíkktsos. nem-aromás heie-foeikkisps csoport; X jelentése -0-, -MM- vagy -NtCI-kV,Y jelentése vagyMpfetű csattal, ahol az A gyűrű olym benzolgyörű, ameiyídott esetben aa alább; helyettesítők kitek! I 3 he-jyetieshóvel sxubsztiruálr ( Π C j ,6 alldfesoport és t2) halogénaiom, Z jelentése Hi-NRXÁú-, (2i-NR:;C0-W!··. (3j -HR%OMRÁ- vagy (4}-C0NX képiei# csoport. ahoi mindegyik helyettesítő jeíentése m 1. igénypontban megadott cs R- jelentése (i)eg;y vagy több hely et; es hővel adott esd ben saohszíituálf fenifcsoport vagy (2'í egy vagy több heíyeííesítövei adott esetben »aubsztkuáit, 5- vagy 6-iagú. monoeikaisos, aromás hete-rocikiüsos csoport. 3. A 2. igényponí sttmnll vegyüiet, ahol R* jekslése • I > C : .i, alkilcsoport, hmeíy adott esetben egv 3 - 8-tagó, monociklusos, nem-aromás heterociklusos csoporttá! yatt ljelyertösitve és a?: utóbbi csoport maga is adott esetben ! - 3 €ő aíPcsoportísi helyetíssMí; vagy (2; C,..8 cikkmik ilesoport 4. A 2. igihvvponí szerinti veg\ ük·, ahol % jelentése -0· 5. A 2. igényponí szerinti vegyidéi, ahol Y'jelentésekcpJetû csoport, ahol nz A gyűrű olyan benxolgyürtk tins# adott csel hers as alábbi «eiyettesfcAk köaül I - i he-lyeitesitovel sxubszutuái?: (1) C;.y aiki lesöpört és (2) iralögénatoav h. A 2* igénypont ssethhi vagy bist als»! 2 jelentése (1) -NHCO- vagy (2) - MHC(> W5Í>··, ahol W#identése C·.,, alkiiéocsoport, (3) -NHCONH- vagy (4) «CÖNH-képleté csoport. % A % igénypíxh: saorlnh vegyid# ahol ÍV jakintése (1)1 -- 3, a?, alábbiak hösSi tsxigváíasztot! h#ct:essíőveí adott esetben saubs/íkaátt (enncsopor;: (s) halogéoatom, (b) I az ÄÄ k&ktoégvÂSÂt xzobsxíltuáit C}..ô alkilcsopon: il) baiögébatoíh . és (4) ciaoocsoport, <e> I, - 3; ax aiábbt&k fchahl «íogválhsatoít hoiyopssMvfet ado® esétben sxöbxKÖiuÄ aikoxksopon: Ö) haiogésnuosst és (is) eipaocsopöA, |d) I 3 daooesoporlíajadbti esetben kilyeftesüeö; C5,.s cMoaSk&soport -és (e> alkinhcxoport, vagy m I - 3,, -m. alábbiak koxai toagyálas^i: helyettes itével adott esetbe« saubsÄÄ 5- vagy b-taga, tneoodkitosos, aronhts heíeroeskiusos csoport; ifíAbalogéastoso, #) I - 3 halogbnatoísaxíl adott esdhsnItelyeiieskeit Cj,$ alksldsopork |c); Q:5xf> cikloalkiicsopon és (d> fenilesopors & Az L igénypont stmntl vegyül«;, atndy 4 Mtôr4* 't3-iCC7^ïa^-2r|;i;ieïk1.^r!ôpï8Êa?&^M^^^sikî $» betíztía«oh4-illöKÍ)i:thll'3>ii'«lanod-tiet;tetl)beöxatrti4 vagy sója. 9, A:X K vegy&H> am# ben«ilaaol#h)os|fénh]v3:<l-cianovl--mctilsiii)feonaanhd:. *&·..&?· 5- igénypont szeifeíí an«% sz fcsri«m^|^aíö^ii0X5'|-:Í «<%. ïî<As 1. ipnypni SKéjrííítí: vegyülei, amely áfa:
- 12. Ás I;. îgêfïypsjîîi: szerinti végète amely sx N-P-«Ííhhw§HP'^PhíM$^^ fenoxij- 1.3 -benal laxol-2- ii ; eíkk^ropánkarboxsmsd vagy sója. 13* -Az 1. igénypont sxermü vegyük:!., IMoxiH^feenztissol-^^^ MvAs !. igénypont vxermtl x-egyület. amely as NÁ7--Cínn^épÁ{íóÁíríi'Siwrmvöi;fpnkiíiv3~íH-karbarnoll}3nu:5c{:ó'eno>:i]-i.3-be«stia2<>í-2-áí}cikk)propánkarboxan'ii<i vagy sója. IS. Az !', IpnypM szerinti vsgyüfeg amely a» N-PAi^o-S-p-ppAiriiMoAömiljpypin'l-iil' karban«)!! ! ammopstoxij-· í .3 -benzliazol-éy il } ctkk^ropsfctkarboxamid. t& Az 1. Ipnypaot tsrnrimi vegyülek aííPno)Íenoxi|~ i .:3iÓ5enzbazöl~2-ö} ciklopropnkpsoxgpä vagy sója.
- 17. Ás I. igénypont szerinti vegyülp amely sæ aóetíf|aPöö)féKbxi] · 1,3*benzUa/o1-2-111 űifelopropáolarbox&mtd. IS, öyögysser. amely magába lbgMegys az J* Igónypm szerinti vegyi! lep. P, Az I. igénypont sæeri-s$«sgyilsí«H.·Sj$gë$«èslèeïi vagy kezeíssóbeo valP alkalmazásra.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008307581 | 2008-12-02 | ||
JP2009125256 | 2009-05-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
HUE026491T2 true HUE026491T2 (hu) | 2016-06-28 |
HUE026491T4 HUE026491T4 (hu) | 2017-07-28 |
Family
ID=42026212
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE09775337A HUE026491T4 (hu) | 2008-12-02 | 2009-12-01 | Benztiazol-származékok mint rákellenes szerek |
Country Status (41)
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR066845A1 (es) * | 2007-06-05 | 2009-09-16 | Takeda Pharmaceutical | Derivados de triazolopiridina e imidazopiridina una composicion farmaceutica que los comprende y su uso en la preparacion de un medicamento para el tratamiento del cancer |
EP2181987B9 (en) * | 2007-08-23 | 2014-09-03 | Takeda Pharmaceutical Company Limited | 2-Carbonylaminobenzothiazoles and their use for the prophylaxis and treatment of cancer |
US8445509B2 (en) | 2008-05-08 | 2013-05-21 | Takeda Pharmaceutical Company Limited | Fused heterocyclic derivatives and use thereof |
US8697874B2 (en) | 2008-12-01 | 2014-04-15 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
WO2013138753A1 (en) * | 2012-03-16 | 2013-09-19 | Fox Chase Chemical Diversity Center, Inc. | Prodrugs of riluzole and their method of use |
JP2015511632A (ja) * | 2012-03-30 | 2015-04-20 | 武田薬品工業株式会社 | メラノーマの治療におけるraf阻害剤およびmek阻害剤の投与 |
CN104736202B (zh) | 2012-08-22 | 2021-09-07 | 康奈尔大学 | 用于抑制肌成束蛋白的方法 |
US9670231B2 (en) | 2013-06-28 | 2017-06-06 | Beigene, Ltd. | Fused tricyclic amide compounds as multiple kinase inhibitors |
SG11201600147TA (en) | 2013-06-28 | 2016-02-26 | Beigene Ltd | Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors |
CN103408541B (zh) * | 2013-07-16 | 2015-04-01 | 浙江医药高等专科学校 | 吲哚取代的噻唑并环己烷类化合物、及其抗肿瘤用途 |
CN103382190B (zh) * | 2013-07-16 | 2015-01-14 | 浙江医药高等专科学校 | 一类噻唑并环己烷类化合物、其制备方法和用途 |
CN103435572B (zh) * | 2013-07-16 | 2015-02-04 | 浙江医药高等专科学校 | 噻唑并环己烷类化合物、其制备方法和抗肿瘤用途 |
CN103435573B (zh) * | 2013-07-16 | 2015-04-01 | 浙江医药高等专科学校 | 苄基取代的噻唑并环己烷类化合物、其制备方法和用途 |
WO2016008048A1 (en) | 2014-07-15 | 2016-01-21 | Ontario Institute For Cancer Research | Methods and devices for predicting anthracycline treatment efficacy |
ES2827024T3 (es) * | 2014-12-23 | 2021-05-19 | Dot Therapeutics 1 Inc | Combinación de inhibidores de Raf y de taxanos |
WO2017066664A1 (en) * | 2015-10-16 | 2017-04-20 | Millennium Pharmaceuticals, Inc. | Combination therapy including a raf inhibitor for the treatment of colorectal cancer |
WO2017165491A1 (en) * | 2016-03-24 | 2017-09-28 | Millennium Pharmaceuticals, Inc. | Use of a pd-1 antagonist and a raf inhibitor in the treatment of cancer |
WO2017165778A1 (en) | 2016-03-24 | 2017-09-28 | Millennium Pharmaceuticals, Inc. | Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments |
TW201735949A (zh) | 2016-03-24 | 2017-10-16 | 千禧製藥公司 | 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法 |
CN109053630B (zh) * | 2018-08-22 | 2022-04-01 | 中国人民解放军第二军医大学 | 一种苯并噻唑类衍生物及其用途 |
US20230148448A9 (en) * | 2018-11-07 | 2023-05-11 | Dana-Farber Cancer Institute, Inc. | Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof |
WO2020232445A1 (en) * | 2019-05-16 | 2020-11-19 | The Regents Of The University Of California | Modulators of pyrimidine nucleotide biosynthetic pathways |
AU2021267373A1 (en) | 2020-05-06 | 2022-12-08 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors |
CN112094248B (zh) * | 2020-09-17 | 2023-05-12 | 中国人民解放军海军军医大学 | 一种取代苯并噻唑类化合物及其用途 |
WO2023086319A1 (en) | 2021-11-09 | 2023-05-19 | Ajax Therapeutics, Inc. | 6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2399026A (en) * | 1941-02-06 | 1946-04-23 | Chem Ind Basel | Amides of 2-aminoarylenethiazoles |
US4096264A (en) * | 1975-12-09 | 1978-06-20 | Merck & Co., Inc. | Certain substituted imidazo [1,2-a] pyridines |
CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
EP1017384B1 (en) | 1997-09-26 | 2004-11-10 | Zentaris GmbH | Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function |
PT1140840E (pt) * | 1999-01-13 | 2006-05-31 | Bayer Pharmaceuticals Corp | Difenilureias substituidas com (.)-carboxiarilo como inibidores de raf-quinase |
EP1140840B1 (en) * | 1999-01-13 | 2006-03-22 | Bayer Pharmaceuticals Corp. | -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
JP2002534468A (ja) | 1999-01-13 | 2002-10-15 | バイエル コーポレイション | p38キナーゼ阻害剤としてのω−カルボキシアリール置換ジフェニル尿素 |
US7928239B2 (en) | 1999-01-13 | 2011-04-19 | Bayer Healthcare Llc | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas |
GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
NZ513006A (en) * | 1999-01-22 | 2003-10-31 | Kirin Brewery | Quinoline derivatives and quinazoline derivatives |
CA2377771A1 (en) | 1999-07-01 | 2001-01-11 | Ajinomoto Co., Inc. | Heterocyclic compounds and medical use thereof |
US7173038B1 (en) | 1999-11-05 | 2007-02-06 | Astrazeneca Ab | Quinazoline derivatives as VEGF inhibitors |
IL151045A0 (en) | 2000-02-07 | 2003-04-10 | Abbott Gmbh & Co Kg | 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors |
WO2001060814A2 (en) | 2000-02-15 | 2001-08-23 | Sugen, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors |
GB0005357D0 (en) | 2000-03-06 | 2000-04-26 | Smithkline Beecham Plc | Compounds |
ES2218391T3 (es) | 2000-03-06 | 2004-11-16 | Smithkline Beecham Plc | Derivados de imidazol como inhibidores de raf-cinasa. |
MXPA02012596A (es) | 2000-06-21 | 2003-04-10 | Hoffmann La Roche | Derivados de benzotiazol. |
CA2423154A1 (en) | 2000-09-21 | 2002-03-28 | David Kenneth Dean | Imidazole derivatives as raf kinase inhibitors |
EP1415987B1 (en) | 2000-10-20 | 2007-02-28 | Eisai R&D Management Co., Ltd. | Nitrogenous aromatic ring compounds as anti cancer agents |
WO2002044156A2 (en) * | 2000-11-29 | 2002-06-06 | Glaxo Group Limited | Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors |
GB0112348D0 (en) | 2001-05-19 | 2001-07-11 | Smithkline Beecham Plc | Compounds |
GB0121494D0 (en) | 2001-09-05 | 2001-10-24 | Smithkline Beecham Plc | Compounds |
GB0121488D0 (en) | 2001-09-05 | 2001-10-24 | Smithkline Beecham Plc | Compounds |
WO2003022837A1 (en) | 2001-09-05 | 2003-03-20 | Smithkline Beecham P.L.C. | Heterocycle-carboxamide derivatives as raf kinase inhibitors |
WO2003022838A1 (en) | 2001-09-05 | 2003-03-20 | Smithkline Beecham Plc | Pyridine substituted furan derivatives as raf kinase inhibitors |
JP2005524668A (ja) | 2002-03-01 | 2005-08-18 | スミスクライン ビーチャム コーポレーション | ジアミノピリミジン類及びそれらの血管新生阻害薬としての使用 |
US8299108B2 (en) | 2002-03-29 | 2012-10-30 | Novartis Ag | Substituted benzazoles and methods of their use as inhibitors of raf kinase |
SI1499311T1 (sl) | 2002-03-29 | 2010-03-31 | Novartis Vaccines & Diagnostic | Substituirani benzazoli in njihova uporaba kot inhibitorji Raf kinaze |
EP2258365B1 (en) | 2003-03-28 | 2013-05-29 | Novartis Vaccines and Diagnostics, Inc. | Use of organic compounds for immunopotentiation |
US7378233B2 (en) * | 2003-04-12 | 2008-05-27 | The Johns Hopkins University | BRAF mutation T1796A in thyroid cancers |
DE10334663A1 (de) * | 2003-07-30 | 2005-03-10 | Merck Patent Gmbh | Harnstoffderivate |
DE10337942A1 (de) | 2003-08-18 | 2005-03-17 | Merck Patent Gmbh | Aminobenzimidazolderivate |
ATE435015T1 (de) | 2003-10-16 | 2009-07-15 | Novartis Vaccines & Diagnostic | Substituierte benzazole und ihre verwendung als raf-kinase-hemmer |
US7846959B2 (en) | 2004-05-07 | 2010-12-07 | Exelixis, Inc. | Raf modulators and methods of use |
MX2007001155A (es) | 2004-07-29 | 2007-08-14 | Creabilis Therapeutics Spa | Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1. |
GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
WO2006071035A1 (en) | 2004-12-31 | 2006-07-06 | Lg Life Sciences, Ltd. | Novel ([1,3]thiazolo[5,4-b]pyridin-2-yl)-2-carboxamide derivatives |
WO2006076376A1 (en) | 2005-01-11 | 2006-07-20 | Medicinova, Inc. | Topical treatment of solid tumors and ocular neovascularization |
EP1841431A4 (en) * | 2005-01-26 | 2009-12-09 | Irm Llc | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS |
EP1907387A1 (en) | 2005-07-11 | 2008-04-09 | Mitsubishi Tanabe Pharma Corporation | An oxime derivative and preparations thereof |
PE20070335A1 (es) | 2005-08-30 | 2007-04-21 | Novartis Ag | Benzimidazoles sustituidos y metodos para su preparacion |
GT200600429A (es) | 2005-09-30 | 2007-04-30 | Compuestos organicos | |
WO2007058482A1 (en) | 2005-11-16 | 2007-05-24 | Lg Life Sciences, Ltd. | Novel inhibitors of protein kinase |
ES2654847T3 (es) | 2006-04-19 | 2018-02-15 | Novartis Ag | Compuestos de benzoxazol y benzotiazol sustituidos en 6-O y métodos para inhibir la señalización CSF-1R |
MX2009001349A (es) | 2006-08-04 | 2009-04-17 | Takeda Pharmaceutical | Derivado heterociclico fusionado y su uso. |
US20100029619A1 (en) | 2006-08-04 | 2010-02-04 | Takeda Pharmaceutical Company Limted | Fused heterocyclic compound |
WO2008084873A1 (ja) | 2007-01-10 | 2008-07-17 | Mitsubishi Tanabe Pharma Corporation | オキシム誘導体 |
JP4328820B2 (ja) | 2007-01-10 | 2009-09-09 | 田辺三菱製薬株式会社 | 医薬組成物 |
CN101260106A (zh) * | 2007-03-06 | 2008-09-10 | 中国药科大学 | Raf激酶抑制剂及其制备方法和用途 |
WO2008125633A2 (en) | 2007-04-13 | 2008-10-23 | Rikshospitalet - Radiumhospitalet Hf | Egfr inhibitors for treatment and diagnosis of metastatic prostate cancer |
AU2008251381B2 (en) | 2007-05-11 | 2014-10-30 | The Johns Hopkins University | Biomarkers for melanoma |
MX2009012626A (es) | 2007-05-23 | 2009-12-07 | Novartis Ag | Inhibidores de raf para el tratamiento de cancer de tiroides. |
AR066845A1 (es) | 2007-06-05 | 2009-09-16 | Takeda Pharmaceutical | Derivados de triazolopiridina e imidazopiridina una composicion farmaceutica que los comprende y su uso en la preparacion de un medicamento para el tratamiento del cancer |
JP2008307581A (ja) | 2007-06-15 | 2008-12-25 | Sanyo Special Steel Co Ltd | 管材の洗浄装置 |
EP2181987B9 (en) | 2007-08-23 | 2014-09-03 | Takeda Pharmaceutical Company Limited | 2-Carbonylaminobenzothiazoles and their use for the prophylaxis and treatment of cancer |
EP2184285B1 (en) | 2007-08-29 | 2015-11-04 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
WO2009028655A1 (ja) | 2007-08-30 | 2009-03-05 | Takeda Pharmaceutical Company Limited | 複素環化合物およびその用途 |
JP2009125256A (ja) | 2007-11-22 | 2009-06-11 | Kandado:Kk | 安眠枕 |
CN101220024A (zh) * | 2007-12-11 | 2008-07-16 | 杜晓敏 | 一组抑制激酶的抗癌化合物 |
US20110081362A1 (en) | 2008-01-31 | 2011-04-07 | The Brigham And Women's Hospital, Inc. | Treatment of cancer |
US20090275546A1 (en) * | 2008-04-10 | 2009-11-05 | Istituto Superiore Di Sanita | Diagnostic tests and personalized treatment regimes for cancer stem cells |
US8445509B2 (en) | 2008-05-08 | 2013-05-21 | Takeda Pharmaceutical Company Limited | Fused heterocyclic derivatives and use thereof |
-
2009
- 2009-11-25 JO JOP/2009/0448A patent/JO3101B1/ar active
- 2009-12-01 UY UY0001032281A patent/UY32281A/es not_active Application Discontinuation
- 2009-12-01 KR KR1020117015343A patent/KR101639092B1/ko active IP Right Grant
- 2009-12-01 ME MEP-2016-203A patent/ME02331B/me unknown
- 2009-12-01 MY MYPI20112494 patent/MY150989A/en unknown
- 2009-12-01 WO PCT/JP2009/070447 patent/WO2010064722A1/en active Application Filing
- 2009-12-01 DK DK09775337.0T patent/DK2358689T5/en active
- 2009-12-01 CN CN200980155786.1A patent/CN102300854B/zh not_active Expired - Fee Related
- 2009-12-01 BR BRPI0922109-3A patent/BRPI0922109A2/pt not_active IP Right Cessation
- 2009-12-01 PT PT97753370T patent/PT2358689E/pt unknown
- 2009-12-01 SG SG2011038247A patent/SG171426A1/en unknown
- 2009-12-01 EP EP09775337.0A patent/EP2358689B9/en active Active
- 2009-12-01 US US12/628,697 patent/US8143258B2/en not_active Expired - Fee Related
- 2009-12-01 PE PE2011001128A patent/PE20110588A1/es active IP Right Grant
- 2009-12-01 CA CA2745144A patent/CA2745144C/en active Active
- 2009-12-01 RS RS20150768A patent/RS54370B9/sr unknown
- 2009-12-01 HU HUE09775337A patent/HUE026491T4/hu unknown
- 2009-12-01 ES ES09775337.0T patent/ES2557304T3/es active Active
- 2009-12-01 PL PL09775337T patent/PL2358689T3/pl unknown
- 2009-12-01 JP JP2011538209A patent/JP5640014B2/ja not_active Expired - Fee Related
- 2009-12-01 NZ NZ593759A patent/NZ593759A/en not_active IP Right Cessation
- 2009-12-01 EA EA201170735A patent/EA019447B1/ru not_active IP Right Cessation
- 2009-12-01 MX MX2011005836A patent/MX2011005836A/es active IP Right Grant
- 2009-12-01 GE GEAP200912278A patent/GEP20146003B/en unknown
- 2009-12-01 SI SI200931334T patent/SI2358689T1/sl unknown
- 2009-12-01 AU AU2009323274A patent/AU2009323274B2/en not_active Ceased
- 2009-12-01 TW TW098140940A patent/TWI436987B/zh not_active IP Right Cessation
- 2009-12-01 AR ARP090104620A patent/AR074435A1/es active IP Right Grant
-
2011
- 2011-05-26 IL IL213184A patent/IL213184A0/en active IP Right Grant
- 2011-05-30 TN TN2011000280A patent/TN2011000280A1/fr unknown
- 2011-06-01 CL CL2011001299A patent/CL2011001299A1/es unknown
- 2011-06-01 DO DO2011000165A patent/DOP2011000165A/es unknown
- 2011-06-23 ZA ZA2011/04659A patent/ZA201104659B/en unknown
- 2011-06-24 CR CR20110366A patent/CR20110366A/es unknown
- 2011-06-29 EC EC2011011165A patent/ECSP11011165A/es unknown
- 2011-06-30 MA MA33985A patent/MA32911B1/fr unknown
- 2011-06-30 CO CO11082152A patent/CO6400140A2/es active IP Right Grant
-
2012
- 2012-01-10 US US13/347,302 patent/US8497274B2/en active Active
- 2012-02-14 HK HK12101435.7A patent/HK1161236A1/zh not_active IP Right Cessation
-
2015
- 2015-12-11 HR HRP20151370TT patent/HRP20151370T1/hr unknown
- 2015-12-15 SM SM201500316T patent/SMT201500316B/it unknown
- 2015-12-17 CY CY20151101155T patent/CY1117178T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2358689T5 (en) | Benzothiazole as anticancer agents. | |
US8344135B2 (en) | Heterocyclic compound and use thereof | |
US8324395B2 (en) | Heterocyclic compound and use thereof | |
US8273741B2 (en) | Imidazo-pyridazinyl compounds and uses thereof | |
US8304557B2 (en) | Fused heterocycle derivatives and use thereof | |
US8445509B2 (en) | Fused heterocyclic derivatives and use thereof | |
US8697874B2 (en) | Heterocyclic compound and use thereof | |
WO2009119776A1 (ja) | 縮合複素環誘導体およびその用途 |